Tag: Georgiamune Menarini
-
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties.FLORENCE, Italy and GAIT…
Latest News
About the Author
Your reliable go-to for precise and up-to-date information!
We are dedicated to accuracy, impartiality, and providing news as it unfolds, earning the trust of a wide audience. Keep up with real-time updates on the latest events and trends.